Relationship between CCR2-V64I polymorphism and cancer risk: a meta-analysis.
The role of CCR2-V64I polymorphism in various cancers has been reported in many studies. However, results from published studies on the association between CCR2-V64I polymorphism and cancer risk are conflicting. Therefore, we performed a meta-analysis to estimate the overall cancer risk associated with the polymorphism. Electronic searches of PubMed and EMBASE were conducted for all publications on the association between this variant and cancer. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to access the strength of this association. Sixteen studies with 2661 cancer patients and 5801 healthy controls were included. Overall, significant association was found between the CCR2-V64I polymorphism and cancer risk (OR=1.84, 95% CI=1.35-2.51, AA vs GA/GG, P=0.37). In the subgroup analysis stratified by cancer types, there was a significant association between this polymorphism and bladder cancer (OR=2.06, 95% CI=1.02-4.15, AA vs GA/GG, P=0.11), cervical cancer (OR=3.34, 95% CI=1.48-7.50, AA vs GG, P=0.56), and oral cancer (OR=2.04, 95% CI=1.46-2.84, GA vs GG, P=0.70). In the subgroup analysis stratified by ethnicities, an increased cancer risk was also found in Europeans (OR=2.31, 95% CI=1.45-3.68, AA vs GA/GG, P=0.16) and Asians (OR=1.88, 95% CI=1.12-3.16, AA vs GA/GG, P=0.92). This meta-analysis suggested that CCR2-V64I polymorphism may contribute to an increased risk of cancer.